Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Non Operating Income (2021 - 2026)

Intellia Therapeutics has reported Non Operating Income over the past 6 years, most recently at $4.3 million for Q1 2026.

  • Quarterly Non Operating Income fell 33.61% to $4.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $26.1 million through Mar 2026, up 72.37% year-over-year, with the annual reading at $28.3 million for FY2025, 85.64% up from the prior year.
  • Non Operating Income was $4.3 million for Q1 2026 at Intellia Therapeutics, up from $2.9 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $10.2 million in Q3 2025 and troughed at -$7.9 million in Q2 2024.
  • The 5-year median for Non Operating Income is $6.6 million (2024), against an average of $3.9 million.
  • Year-over-year, Non Operating Income tumbled 2306.02% in 2022 and then soared 464.03% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$3.3 million in 2022, then surged by 332.86% to $7.7 million in 2023, then dropped by 2.35% to $7.5 million in 2024, then plummeted by 61.27% to $2.9 million in 2025, then surged by 47.09% to $4.3 million in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Non Operating Income are $4.3 million (Q1 2026), $2.9 million (Q4 2025), and $10.2 million (Q3 2025).